平成２６年３月２日 ２０１４年 日曜日
今朝はタイトルの医療費一考を！！
慢性疾患で薬を飲み続ける必要のある患者にとって
医療費負担は結構高額
でもでも
日本では皆保険制度で贅沢
ジェネリックを利用する人はまだまだ少ないが！！
今朝は平成２６年２月３日現在の厚労省の薬価を眺めていました。
１万８０００品目：１２６ページも表が続くので大変です。
まあ放射性医薬品が高いのは理解できるが
それでも１セットが何十万何百万円にはヒエッー！！！
何万円クラスもザラです。
１錠が数千円もザラです。
そして本日のタイトル
インドは世界の薬の首都関連のニュースです。
昨年４月の報道です。
グリベックって医薬品の特許会社：最近何かと問題のNovartisが
インドの最高裁で敗訴
日本の薬価では１００ｍｇ１錠が２７４９円
人によっては１日４００ｍｇ服用：まあ１日１万円：月３０万円
裁判では先発品では月２６万円が、ジェネリックでは１万７５００円
インドの裁判所は庶民、患者の味方です。
日本のように皆保険で高額医療費制度救済なんて世界唯一の？特別の国
国の医療費赤字もうなづけるが、世界は甘くなく
インドは地球、世界の薬の首都として
画期的判断
やっぱベトナムって医療費も治療も患者や高齢者に優しくいい国って思いました。
本日の血液検査８項目も受付から診断結果まで１時間内で費用は１０００円
私しゃ今朝のネット勉強でさらにベトナムにサイゴンに感謝しました。
これから血液検査に行ってきます。
何となくルンルン
きっといい結果が！！
１回目の休憩
午前６時６分
読みたい人は下記をどうぞ！！
Samantha Stainburn and Jason OverdorfApril 1, 2013 09:41
Add Samantha Stainburn and Jason Overdorf to your circles
India: Supreme Court denies patent for Novartis drug Gleevec
India’s Supreme Court has rejected a bid from Swiss pharmaceutical company Novartis AG to patent an updated version of its cancer drug Gleevec.
NEW DELHI, India ― India’s Supreme Court has rejected a bid from Swiss pharmaceutical company Novartis AG to patent an updated version of its cancer drug Gleevec (known as Glivec in Europe).
Patents allow companies to block competitors from making and selling the same product. The ruling means that Novartis can’t stop drug makers in India from manufacturing generic versions of Gleevec, which cost much less than the original.
According to the Guardian, Gleevec costs about $2,600 a month, while Indian copycat versions run just $175 a month.
By taking a strong position against "evergreening" patents, the court's ruling signals that India aims to protect its generic drug industry, despite adopting more stringent patent laws to conform with World Trade Organisation rules in 2005.
While that may cost India's fast growing research and development industry, it will come as a tremendous boon to ordinary people, potentially extending low-cost treatments from HIV ― where Indian companies pioneered low-cost medicines by ignoring patents ― to drugs for cancer and even chronic diseases like diabetes.
India’s patent law allows companies to patent medicines discovered after 1995, according to the New York Times. The court ruled that the version of Gleevec presented to them, while formulated after 1995, was not different enough from an early version of the drug that Novartis patented in 1993 and later abandoned.
Since the drug is not a novel invention, it does not qualify for patent protection, the judges said.
“The judgment in the Novartis case is a victory for patients both in India and around the world,” Dr. Yusuf K. Hamied, chairman of Indian generic drug company Cipla, told the New York Times. “India, being the pharmacy capital of the world, can continue to produce affordable, high-quality medicines without the threat of patents for minor modifications of known medicines.”
Novartis condemned the rulingin a statement, saying it “discourages innovative drug discovery essential to advancing medical science for patients.”
Aid groups and patient advocates cheered the decision. "The difference in price was huge,” YK Sapru, of the Mumbai-based cancer patients' association, told the Guardian. “The generic version makes it affordable to so many more poor people, not just in India, but across the world.”
More from GlobalPost: Apple denied iPad Mini trademark by US Patent and Trademark Office
http://www.globalpost.com/dispatch/news/regions/asia-pacific/india/130401/india-supreme-court-denies-patent-novartis-drug-glee
この下のクリックお願いします！！！
↓↓↓↓↓
http://blog.goo.ne.jp/admin/newentry/#
